Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis

Abstract Background: Hyperhomocysteinemia is associated with autoimmune diseases such as ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Current findings regarding plasma/serum homocysteine (HCY) levels in AS patients are inconsistent. This study aims to systematically evaluate the association between circulating HCY levels and AS. Methods: Online electronic databases (PubMed, Web of Science, Embase, ScienceDirect, China National Knowledge Infrastructure (CNKI), and Wanfang data) were used to retrieve all relevant articles published up to May 7, 2020. The pooled standardized mean difference (SMD) with 95% confidence interval (CI) was calculated using the random-effect model, Stata16 software. Results: Nine articles containing 778 AS patients and 522 controls were included in this meta-analysis. No significant differences in HCY levels were found between AS and control groups (pooled SMD = 0.46, 95% CI = − 0.30 to 1.23, P = 0.23). However, subgroup analysis suggested that HCY levels were significantly higher (P < 0.05) in the AS group treated with methotrexate (MTX) compared with the control group. In contrast, HCY levels were significantly (P < 0.05) lower in the AS group receiving anti-TNF-α treatment compared with the control group. No significant differences were detected between HCY levels and disease activity scores (Bath AS disease activity index, BASDAI), and methylenetetrahydrofolate reductase (MTHFR) C677T genotype. Conclusion: This meta-analysis indicates that HCY levels are similar between AS and controls, and do not correlate with disease activity. However, different medical treatments cause fluctuations of circulating HCY levels in AS patients. Further and larger-scale studies are needed to confirm these findings. Trial registration: This study was registered at international prospective register of systematic reviews (PROSPERO), registration number: CRD42020184426.

Saved in:
Bibliographic Details
Main Authors: Li,Hui-hui, Li,Xue-quan, Sai,Lin-tao, Cui,Yi, Xu,Jia-hui, Zhou,Chi, Zheng,Jing, Li,Xing-fu, Liu,Hua-xiang, Zhao,Ying-jie
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Reumatologia 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062021000100214
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2523-31062021000100214
record_format ojs
spelling oai:scielo:S2523-310620210001002142021-03-18Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysisLi,Hui-huiLi,Xue-quanSai,Lin-taoCui,YiXu,Jia-huiZhou,ChiZheng,JingLi,Xing-fuLiu,Hua-xiangZhao,Ying-jie Homocysteine Meta-analysis Ankylosing spondylitis Controls Abstract Background: Hyperhomocysteinemia is associated with autoimmune diseases such as ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Current findings regarding plasma/serum homocysteine (HCY) levels in AS patients are inconsistent. This study aims to systematically evaluate the association between circulating HCY levels and AS. Methods: Online electronic databases (PubMed, Web of Science, Embase, ScienceDirect, China National Knowledge Infrastructure (CNKI), and Wanfang data) were used to retrieve all relevant articles published up to May 7, 2020. The pooled standardized mean difference (SMD) with 95% confidence interval (CI) was calculated using the random-effect model, Stata16 software. Results: Nine articles containing 778 AS patients and 522 controls were included in this meta-analysis. No significant differences in HCY levels were found between AS and control groups (pooled SMD = 0.46, 95% CI = − 0.30 to 1.23, P = 0.23). However, subgroup analysis suggested that HCY levels were significantly higher (P < 0.05) in the AS group treated with methotrexate (MTX) compared with the control group. In contrast, HCY levels were significantly (P < 0.05) lower in the AS group receiving anti-TNF-α treatment compared with the control group. No significant differences were detected between HCY levels and disease activity scores (Bath AS disease activity index, BASDAI), and methylenetetrahydrofolate reductase (MTHFR) C677T genotype. Conclusion: This meta-analysis indicates that HCY levels are similar between AS and controls, and do not correlate with disease activity. However, different medical treatments cause fluctuations of circulating HCY levels in AS patients. Further and larger-scale studies are needed to confirm these findings. Trial registration: This study was registered at international prospective register of systematic reviews (PROSPERO), registration number: CRD42020184426.info:eu-repo/semantics/openAccessSociedade Brasileira de ReumatologiaAdvances in Rheumatology v.61 20212021-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062021000100214en10.1186/s42358-021-00175-7
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Li,Hui-hui
Li,Xue-quan
Sai,Lin-tao
Cui,Yi
Xu,Jia-hui
Zhou,Chi
Zheng,Jing
Li,Xing-fu
Liu,Hua-xiang
Zhao,Ying-jie
spellingShingle Li,Hui-hui
Li,Xue-quan
Sai,Lin-tao
Cui,Yi
Xu,Jia-hui
Zhou,Chi
Zheng,Jing
Li,Xing-fu
Liu,Hua-xiang
Zhao,Ying-jie
Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
author_facet Li,Hui-hui
Li,Xue-quan
Sai,Lin-tao
Cui,Yi
Xu,Jia-hui
Zhou,Chi
Zheng,Jing
Li,Xing-fu
Liu,Hua-xiang
Zhao,Ying-jie
author_sort Li,Hui-hui
title Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
title_short Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
title_full Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
title_fullStr Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
title_full_unstemmed Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
title_sort association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
description Abstract Background: Hyperhomocysteinemia is associated with autoimmune diseases such as ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Current findings regarding plasma/serum homocysteine (HCY) levels in AS patients are inconsistent. This study aims to systematically evaluate the association between circulating HCY levels and AS. Methods: Online electronic databases (PubMed, Web of Science, Embase, ScienceDirect, China National Knowledge Infrastructure (CNKI), and Wanfang data) were used to retrieve all relevant articles published up to May 7, 2020. The pooled standardized mean difference (SMD) with 95% confidence interval (CI) was calculated using the random-effect model, Stata16 software. Results: Nine articles containing 778 AS patients and 522 controls were included in this meta-analysis. No significant differences in HCY levels were found between AS and control groups (pooled SMD = 0.46, 95% CI = − 0.30 to 1.23, P = 0.23). However, subgroup analysis suggested that HCY levels were significantly higher (P < 0.05) in the AS group treated with methotrexate (MTX) compared with the control group. In contrast, HCY levels were significantly (P < 0.05) lower in the AS group receiving anti-TNF-α treatment compared with the control group. No significant differences were detected between HCY levels and disease activity scores (Bath AS disease activity index, BASDAI), and methylenetetrahydrofolate reductase (MTHFR) C677T genotype. Conclusion: This meta-analysis indicates that HCY levels are similar between AS and controls, and do not correlate with disease activity. However, different medical treatments cause fluctuations of circulating HCY levels in AS patients. Further and larger-scale studies are needed to confirm these findings. Trial registration: This study was registered at international prospective register of systematic reviews (PROSPERO), registration number: CRD42020184426.
publisher Sociedade Brasileira de Reumatologia
publishDate 2021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062021000100214
work_keys_str_mv AT lihuihui associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT lixuequan associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT sailintao associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT cuiyi associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT xujiahui associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT zhouchi associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT zhengjing associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT lixingfu associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT liuhuaxiang associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
AT zhaoyingjie associationofhomocysteinewithankylosingspondylitisasystematicreviewandmetaanalysis
_version_ 1756441911298621440